Table 1.
—Baseline Patient Characteristics (n = 117)
| Variable | Value |
| Age, y, mean (SD) | 59.7 (10.4) |
| Male, % | 96.6 |
| Race, % | |
| Black | 47.9 |
| White | 44.4 |
| Othera | 7.7 |
| Married,b % | 47.9 |
| Medical comorbiditiesc | |
| Charlson Index, median (IQR) | 2 (1-4) |
| Hypertension, % | 86.3 |
| Diabetes mellitus, % | 69.2 |
| Coronary artery disease, % | 49.6 |
| Hyperlipidemia | 91.5 |
| Chronic obstructive lung disease, % | 34.2 |
| BMI, kg/m2, mean (SD) | 35.1 (6.7) |
| Epworth Sleepiness Scale, mean (SD) | 11.9 (5.5) |
| Apnea-hypopnea index, mean (SD) | 40.2 (25.5) |
| Type of diagnostic sleep study, in-laboratory (vs home, unattended), % | 53.9 |
| Total number of d in lipid-lowering drug exposure window, y before CPAP initiation, median (range)d | 365 (208-365) |
| Total patient-d of CPAP observation, number | 787 |
| Number of CPAP patient-d observed per subject,e median (range) | 7 (1-7) |
| Median h of CPAP use per d, across all patient-d, median (IQR) | 4.1 (0.1-6.4) |
CPAP = continuous positive airway pressure; ICD-9 = International Classification of Disease, 9th ed.; IQR = interquartile range.
Other race category consists of Pacific Islander, Asian, and Indian American (n = 5), and race classification missing (n = 4).
Nonmarried patients: separated/divorced (26.5%), never married (19.7%), widowed (6.0%).
Medical comorbidities measured according to ICD-9 classification. Of the 10 subjects on lipid-lowering therapy without an ICD-9 diagnosis of hyperlipidemia, seven had comorbid diagnoses of diabetes mellitus and one had comorbid coronary artery disease.
Drug ascertainment exposure window is defined as a minimum 180 and a maximum 365 d before CPAP initiation.
A full 7 patient-d on CPAP were observed for 103 (88.0%) of subjects; 6 patient-d were observed for eight (6.8%); and ≤5 patient-d on CPAP for six (5.1%) of the 117 subjects.